Arkolith/Insider Trading/XERS/Form 4

Shannon John Patrick Jr

See Remarks, DirectorXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Feb 2, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2026Tax withholding(F)111K$7.36$815K2.9M
Jan 31, 2026Tax withholding(F)112K$7.36$822K3.0M
Jan 31, 2026Tax withholding(F)118K$7.36$869K3.2M
Jan 30, 2026Grant(A)478K—$03.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 30, 2026Grant(A)640K—$0640K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001553595-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML